XBiotech (NASDAQ:XBIT) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of XBiotech (NASDAQ:XBIT – Get Rating) in a research report report published on Thursday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

XBiotech Price Performance

XBiotech stock opened at $3.42 on Thursday. XBiotech has a 12-month low of $3.00 and a 12-month high of $9.79. The business’s 50-day moving average price is $3.83 and its two-hundred day moving average price is $3.64. The stock has a market cap of $104.10 million, a PE ratio of -2.87 and a beta of 1.20.

Institutional Trading of XBiotech

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD grew its holdings in shares of XBiotech by 21.8% during the second quarter. Price T Rowe Associates Inc. MD now owns 17,600 shares of the biopharmaceutical company’s stock worth $99,000 after purchasing an additional 3,146 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of XBiotech by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 155,083 shares of the biopharmaceutical company’s stock worth $544,000 after purchasing an additional 3,342 shares during the last quarter. Swiss National Bank grew its holdings in shares of XBiotech by 8.8% during the first quarter. Swiss National Bank now owns 46,800 shares of the biopharmaceutical company’s stock worth $404,000 after purchasing an additional 3,800 shares during the last quarter. PDT Partners LLC grew its holdings in shares of XBiotech by 29.9% during the second quarter. PDT Partners LLC now owns 16,976 shares of the biopharmaceutical company’s stock worth $96,000 after purchasing an additional 3,912 shares during the last quarter. Finally, BlackRock Inc. grew its holdings in shares of XBiotech by 1.6% during the third quarter. BlackRock Inc. now owns 258,934 shares of the biopharmaceutical company’s stock worth $938,000 after purchasing an additional 4,002 shares during the last quarter. 10.06% of the stock is currently owned by institutional investors.

About XBiotech

(Get Rating)

XBiotech, Inc is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. Its product pipeline includes oncology, infectious diseases, dermatology and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.